Research programme: HDAC inhibitors - Onkure TherapeuticsAlternative Names: ONK-102
Latest Information Update: 07 Jul 2016
At a glance
- Originator OnKure Therapeutics
- Class Antineoplastics
- Mechanism of Action HDAC1 protein inhibitors; HDAC6 protein inhibitors; Histone deacetylase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer